Canada markets closed

Hofseth BioCare ASA (0Q6H.L)

LSE - LSE Delayed Price. Currency in NOK
Add to watchlist
3.0100-0.2900 (-8.79%)
At close: 09:56AM GMT
Full screen
Previous Close3.3000
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's Range0.0000 - 0.0000
52 Week Range
Volume35,510
Avg. Volume35,386
Market CapN/A
Beta (5Y Monthly)0.47
PE Ratio (TTM)N/A
EPS (TTM)-0.3780
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Hofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT

    HBC had gross operating revenues of NOK 47.4m (33.6m) in the fourth quarter and NOK 218.5m (120.4m) for the full year. Adjusted for the sale of assets in the second quarter, operating revenues were NOK 194.9m for the full year, representing an increase compared to 2022 of 38 percent. Cash and cash equivalents increased by NOK 6.2m during the quarter, leaving total holding at NOK 23.9m at the end of the year, compared to NOK 32.4m at the end of 2022. Including credit facilities, HBC had NOK 62.5m

  • GlobeNewswire

    Hofseth Biocare ASA: HBC Immunology Inc successfully completes first animal model of prostate cancer with FT-005 in combination with hormonal (anti-androgen) therapy demonstrating significant anti-tumour activity

    HBC Immunology Inc. (70.6% owned by Hofseth BioCare ASA) reports today the successful completion of the first in vivo study within its prostate cancer development program. The study assessed whether the combination of targeted hormonal therapy, bicalutamide, and FT-002 or FT-005 was better at suppressing PC3 tumour growth compared to control (no treatment). PC3 represents a model of very aggressive prostate cancer which is resistant to standard treatment. The FT peptides are HBCI’s two leading d

  • GlobeNewswire

    Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED

    Reference is made to the stock exchange announcement on 4 January 2024 regarding the conclusion of an extraordinary general meeting in Hofseth Biocare ASA ("HBC" or the "Company") whereby the general meeting resolved, among other things, an issuance of new preference class B shares in connection with the NOK 144 million investment from Hofseth International AS ("HI"). Following the registration of the share capital increase in the Norwegian Registry for Business Enterprises, the Company's share